Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

NCT05136456

Primary Membranous Nephropathy

UNKNOWN PHASE2

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

NCT04154670

Healthy Renal Insufficiency

COMPLETED PHASE1

Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

NCT05845762

Idiopathic Membranous Nephropathy

UNKNOWN

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

NCT07289763

Primary Membranous Nephropathy

NOT_YET_RECRUITING PHASE2

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

NCT02063100

Glomerulonephritis Proteinuria

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Membranous Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Losartan Tablets & QingReMoShen Granule

Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.

Group Type EXPERIMENTAL

Losartan Tablets & QingReMoShen Granule

Intervention Type DRUG

Losartan Tablets & Placebo Granule

Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.

Group Type PLACEBO_COMPARATOR

Losartan Tablets & Placebo Granule

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Losartan Tablets & QingReMoShen Granule

Intervention Type DRUG

Losartan Tablets & Placebo Granule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy;
* 6.0g≥24 hour urinary protein≥1.0g;
* serum albumin concentration≥26g/L;
* Chronic Kidney Disease (CKD)≤3 stage (eGFR\>30ml/min/1.73m2 MDRD);
* Willing to participate in the trial and signed an informed consent.

Exclusion Criteria

* Secondary membranous nephropathy;
* Patients with one of the following circumstances- malignant tumors or malignancy, HIV infection, a history of mental illness, any serious systemic infection, serious gastrointestinal diseases, circulating hepatitis B surface antigens positive or persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes mellitus;
* Pregnant and lactating women;
* Undergoing other clinical trials.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No